Stay updated on IGN002 Clinical Trial in Refractory NHL
Sign up to get notified when there's something new on the IGN002 Clinical Trial in Refractory NHL page.

Latest updates to the IGN002 Clinical Trial in Refractory NHL page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a Phase 1 extension study for the IGN002 treatment for Non-Hodgkin Lymphoma, while adding information about the study's collaborators and a revision number update.SummaryDifference34%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to IGN002 Clinical Trial in Refractory NHL
Enter your email address, and we'll notify you when there's something new on the IGN002 Clinical Trial in Refractory NHL page.